Hemispherx Biopharma, Inc., headquartered in
Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated
to treating and preventing chronic viral and immune-based disorders
through the development and manufacturing of compounds that enhance
the natural immune system of the human body.
The Company’s flagship products include
Alferon N Injection® and the experimental immunotherapeutics
Ampligen®. Its platform technology includes large and small agents
for potential treatment of various chronic viral
Ampligen®, is a new class of
specifically-configured ribonucleic acid (RNA) compounds targeted at
such important diseases as Chronic Fatigue
Syndrome/Myalgic Encephalomyelitis (CFS/ME),
HIV, Hepatitis B,
Hepatitis C, and cancers including
kidney cancer and metastatic
Alferon N Injection® (interferon alfa-n3, human
leukocyte derived) is a highly purified, natural source, glycosylated, multi-species alpha interferon product, composed of
eight forms of high-purified alpha interferon. It is the only
natural source, multi-species alfa interferon currently sold in the
United States and is also approved for sale Argentina. Alferon N Injection®
is the company’s registered trademark for it’s injectible
formulation or natural alpha interferon approved by the FDA for the
treatment of genital HPV (refractory condylomata acuminata).
Alferon N Injection® may also have activity against other viral
infections such as Multiple Sclerosis, Hepatitis C, HIV, West Nile Virus,
and SARS, but has not been approved for that use.
Hemispherx is also actively engaged in broad-based ongoing
experimental studies assessing the efficacy of their products
Alferon N Injection® and Alferon LDO® against influenza viruses as
an adjuvant and/or single agent antiviral.